FDA Orange Book · active-ingredient family
Albuterol sulfate; budesonide
Albuterol sulfate; budesonide is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:AIRSUPRA · NDA 214070
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
2
Exclusivity periods
Brand (NDA) products · aerosol, metered
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| AIRSUPRARLD | ASTRAZENECA | NDA 214070 | — | Jan 10, 2023 |
Marketing exclusivity (2)
- M-317New use / labeling-change exclusivity (3 years)
Sep 15, 2028
in 2 yr 3 mo
- NPNew product exclusivity (3 years)
Jan 10, 2026
5 mo ago
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9415009 | May 28, 2030 | in 4 yr | U-3509 |
Albuterol sulfate; budesonide — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

